Exhibit 99.1
FORM 51-102F3
MATERIAL CHANGE REPORT
Item 1 Name and Address of Company
Aeterna Zentaris Inc. (the “Company”)
c/o Stikeman Elliott LLP
5300 Commerce Court West
199 Bay Street
Toronto, Ontario
M5L 1B9
Item 2 Date of Material Change
October 4, 2019.
Item 3 News Release
On October 4, 2019, the Company issued a news release indicating the material change, which was disseminated on the GlobeNewswire news service.
Item 4 Summary of Material Change
On October 4, 2019, the Company announced the appointment of Klaus Paulini as President and Chief Executive Officer of the Company, effective October 4, 2019, replacing Michael Ward. Dr. Paulini will also serve as a Director of the Company.
Item 5.1 Full Description of Material Change
On October 4, 2019, the Company announced the appointment of Klaus Paulini as President and Chief Executive Officer of the Company, effective October 4, 2019, replacing Michael Ward. Dr. Paulini will also serve as a Director of the Company.
Dr. Paulini will continue to be based in Frankfurt, Germany, and his appointment as President and Chief Executive Officer aligns with the Company’s refocus on its operations in Germany. The Company’s registered office will remain in Toronto, Ontario, Canada.
Dr. Paulini began his career in the pharmaceutical industry at ASTA Medica AG in 1997. He had an active role in the spinoff and formation of Aeterna Zentaris GmbH from ASTA Medica. Dr. Paulini has managed many of the Company’s clinical development projects including research and development of Macrilen™ (macimorelin). Dr. Paulini obtained his PhD (Dr. Ing.) in chemistry at the Technical University Darmstadt (Germany) in 1993 and specialized in medicinal chemistry and drug discovery during subsequent postdoctoral fellowships at Strathclyde University (Glasgow, Scotland) and J.W. Goethe University (Frankfurt, Germany).
Item 5.2 Disclosure for Restructuring Transactions
Not applicable.
Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102
Not applicable.
- 2 - |
Item 7 Omitted Information
Not applicable.
Item 8 Executive Officer
Further information regarding the matters described in this report may be obtained from Leslie Auld, Chief Financial Officer, at 843-900-3201 or IR@AEZSinc.com.
Item 9 Date of Report
October 8, 2019